Episode Details
Back to Episodes
Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Published 1 year, 1 month ago
Description
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.